MDA

28533

MDA is an entactogen and stimulant that can provide some psychedelic effects. It’s often compared to MDMA, which it resembles in many ways. They differ in that MDA is usually more stimulating, more psychedelic, and lasts a little longer.

The drug has been used recreationally since the 1960s and research began earlier in the 1900s. Much like MDMA, it may be useful in psychotherapy.

Neurotoxicity is a concern with the substance, which is why minimizing your use, taking common doses, keeping your temperature low, and supplementing are important.


MDA = Sass; Sassafras; tenamfetamine; 3,4-methylenedioxyamphetamine


Dose

Oral

Light: 75 – 100 mg

Common: 100 – 150 mg

Strong: 150+ mg


Timeline

Oral

Total: 5 – 7 hours

Onset: 00:20 – 01:00 (for most people)


Experience Reports

Erowid



Test Results

 

 


References

(2010) Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans

(2006) Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques.

(2005) Serotonergic neurotoxic metabolites of ecstasy identified in rat brain.

(2004) The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity.

(2001) An exploration of the history and controversies surrounding MDMA and MDA.

(1997) 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations.

(1996) Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning.

(1995) The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.

(1994) Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors.

(1991) 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine.

(1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity.

(1987) 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.

(1986) The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.

(1986) Ecstacy: a review of MDMA and MDA.

(1981) Methylenedioxyamphetamine: Clinical Description of Overdose, Death, and Review of Pharmacology

(1974) Methylenedioxyamphetamine (MDA)–Subjective Effects

(1973) The properties of 3,4-methylenedioxyamphetamine (MDA). I. A review of the literature.

(1972) A Fatal Case Involving Methylenedioxyamphetamine

(1967) Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy.

Category Tag